ClinicalTrials.gg
Active, not recruitingNCT04416490OCEANUpdated Sep 12, 2025

Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer

An observational study in Stage II Colon Cancer and Stage III Colon Cancer, sponsored by Boryung Pharmaceutical Co., Ltd. Active, not recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Boryung Pharmaceutical Co., Ltd · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,013
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 82 studies in Colonic Neoplasms with a site in Korea, Republic of — 13 open to participants now, 29 under way, 10 of them phase 3. Colonic Neoplasms · Korea, Republic of.

Enrollment
5th of 15
2,013 · median 300
Started
2020
with 5 others
Observational
15 of 82
1 open now
Primary completion
2027-02
later than 16 of 28 live
Registered
52nd of 82
by date

Among the 82 studies in Colonic Neoplasms with a site in Korea, Republic of, this one is the 5th largest by enrollment of the 15 observational ones that give a count, is one of 6 that started in 2020, is one of 15 observational ones, reaches primary completion later than 16 of the 28 other live ones, and was the 52nd registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

13 of the 82 studies in Colonic Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 328 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Colonic Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

According to general medical guidelines, adjuvant chemotherapy is used after curative resection of high-risk stage II or III primary colon cancer. However, there exist limitations using clinical trial data acquired from highly selected subjects in a controlled environment. For example, patients aged over 70 years old were in many cases excluded from clinical trials resulting in insufficient data on the efficacy of therapies including oxaliplatin in aged patients, and the source data of the medical guidelines did not fully reflect the conditions of Korean patients. In addition, suggestions are continuously being submitted for existing therapies with modified administration periods and methods with the aim to search for the optimum effect over side effects. Discussions are also held on meta analyses results that imply the need to apply slightly different approaches through small groups of patient and disease factors. As there are more diverse adjuvant therapy protocols that can be applied to post-surgery colon cancer patients, it is necessary to figure out the patterns of adjuvant chemotherapies actually used in Korean medical practices. Also, in order to complement the limitation of external validity of the existing base clinical data, a multifaceted exploratory analysis will be conducted by making follow-up observations on patterns, prognosis results, quality of life, adverse effects, etc. of post-surgery adjuvant chemotherapies actually used in around 30 sites in Korea under the noninterventional observational study conditions.

Read the detailed description

[Overview] Investigators will obtain voluntary consent for participation in this study from patients with high-risk stage II or stage III colon cancer who require or are planning to receive adjuvant chemotherapy after curative resection. Patients who provided written consent for using their personal information and who satisfy inclusion/exclusion criteria will be given a study enrollment number. Among the predefined study-relevant data, available data on these patients will be collected in the case report forms (CRF) until the study is completed.

[Follow-up observation schedule and the scope of data collection] Since this study is an observational study, data collection in the CRF will be restricted to the data created only from usual treatment practices and there will be no separate test or additional drug administration for the study. However, subjects will be asked to complete questionnaire to evaluate their quality of life at the following time points: baseline, Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks). For subjects who drop out from the study or in case of disease event (relapse, metastasis or new primary malignant tumor), the questionnaire will be conducted at the time of drop-out or disease event. Survival of all subjects (including those who drop out from the study or whose disease event is confirmed) will be checked every 6 months after adjuvant chemotherapy started. Among the data created from the subjects on their visits for treatment, the following data will be collected for the purpose of this study.

  • Demographics of the subjects.
  • Colon cancer information (diagnosis information, risk factors, surgery information).
  • Whether or not neoadjuvant chemotherapy was conducted.
  • Underlying disease.
  • Adjuvant chemotherapy information.
  • Other concomitant medication (drugs administered for prevention and treatment of OXLIPN, drugs administered for treatment of Grade 3-4 adverse drug reactions/serious adverse drug reactions related to the chemotherapy).
  • Vital signs, height, and weight.
  • Performance Status evaluation (ECOG PS).
  • Geriatric Assessment (KG-7): for subjects ≥ 65 years old.
  • Quality of Life assessment (FACT-C, FACT/GOG-NTX-12).
  • Laboratory test results.
  • Tumor Marker (CEA, CA 19-9) test results.
  • Molecular genetic test results (MSI [microsatellite instability] and/or MMR [DNA mismatch repair gene], immunohistochemistry test for protein, KRAS, NRAS, BRAF etc.).
  • Colonoscopy/CT results.
  • Disease event (relapse, metastasis or new primary malignant tumor).
  • Survival of subjects.
  • Oxaliplatin-induced Peripheral Neuropathy (OXLIPN): Only when oxaliplatin is administered.
  • Grade 3-4 adverse drug reactions related to chemotherapy (based on CTCAE v.5.0).
  • Serious adverse drug reactions.
03

Conditions studied

  • Stage II Colon Cancer
  • Stage III Colon Cancer

Browse trials for

Keywords

  • colon cancer
  • high-risk stage
  • curative resection
  • adjuvant chemotherapy
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with high-risk stage II or stage III primary colon cancer who have received curative resection. Approximately 2,000 subjects.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects are given explanations about the study objectives and methods, and will express their consent by signing a written agreement to use their personal information.
  2. Male and female adult subjects who are ≥ 19 years old.
  3. Subjects are confirmed to have primary colon cancer through histological diagnosis and are at *high-risk stage II (T3/4, N0M0) or stage III (any T, N1/2, M0).

    • High-risk stage II is determined when one or more of the following are applicable.

      1. Cancer is at T4 stage (stage IIB,IIC);
      2. Cancer cell differentiation grade is 3 or 4 (poor histologic grade);
      3. Cancer cells are present in lymphatic or blood vessels around the tumor (peritumoral lymphovascular involvement);
      4. Ileus was present during surgery (bowel obstruction at presentation);
      5. Cancer is at T3 stage with localized perforation or there are indeterminate cancer cells residual on the incisal surface. (T3 lesions with localized perforation or close, indeterminate, or positive margins); or,
      6. Cancer cells invaded into the area around the ganglion (perineural invasion).
  4. Subjects are decided to require chemotherapy including oxaliplatin and/or capecitabine after curative resection (E.g.: FOLFOX, CapeOx or Capecitabine and modified therapies).
  5. Subjects' performance status score ( PS) is 2 or lower (0, 1, 2).

Exclusion criteria

Exclusion Criteria:

  1. Subjects are diagnosed with other primary cancers that can influence the treatment or prognosis of primary rectal and colon cancers.
  2. Subjects are diagnosed with or secondary colon cancer.
  3. Subjects with Stage 0/1 (Tis/1/2, N0M0) or Stage IV (any T, any N, M1) colon cancer.
  4. Subjects who are currently on chemotherapy after curative resection.
  5. Subjects who are receiving palliative chemotherapy.
  6. Pregnant and breast-feeding subjects.
  7. Subjects who are currently participating in other clinical trials (clinical trials for drugs or medical devices) or are planning to participate in other clinical trials during the duration of this study. However, subjects participating in a noninterventional observational study or a registry study can participate in this study.
  8. Other subjects who are not suitable for study participation upon the investigator's decision.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,013 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients

    Patients with high-risk stage II or stage III primary colon cancer who have received curative resection

06

What researchers measure

Primary outcomes

  1. Type of adjuvant chemotherapy

    Type of adjuvant chemotherapy that were used.

    Time frame: through adjuvant chemotherapies completion, an average of 24 weeks

  2. Frequency of adjuvant chemotherapy

    Frequency of adjuvant chemotherapy that were used.

    Time frame: through adjuvant chemotherapies completion, an average of 12 cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days)

  3. Disease Free Survival (DFS)

    Time from the date of resection surgery to the date of first relapse,

    Time frame: From date of resection surgery until the date of first documented progression, assessed up to 36 months

  4. Overall Survival (OS)

    Time from the date of resection surgery to the date of death.

    Time frame: From date of resection surgery until the date of death, assessed up to 36 months

Secondary outcomes

  1. Characteristics of relapsed and metastasis cancers and new primary malignant tumor list.

    Whether locally relapsed, whether metastasis is present, location of metastasis, etc.

    Time frame: up to 36 months

  2. Quality of Life Assessment (FACT-C)

    Subjects will be asked to complete questionnaires to evaluate their quality of life

    Time frame: Baseline, Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks)

  3. Quality of Life Assessment (FACT/GOG-NTX-12)

    Subjects will be asked to complete questionnaires to evaluate their quality of life

    Time frame: Baseline, Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks)

Other outcomes

  1. Adverse drug reactions/serious adverse drug reactions

    Overall incidence of grade 3-4 adverse drug reactions/serious adverse drug reactions

    Time frame: From the date of adjuvant chemotherapy started until the end of follow-up(36 month)

  2. Oxaliplatin Induced Peripheral Neuropathy, OXLIPN

    Overall incidence of Oxaliplatin Induced Peripheral Neuropathy, OXLIPN

    Time frame: From the date of adjuvant chemotherapy started until the end of follow-up(36 month)

  3. Performance Status (ECOG) evaluation results

    Frequency and ratio of ECOG evaluation results will be presented by time point.

    Time frame: Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks)

  4. Results on weight

    Descriptive statistics will be presented for the results of weight by time point.

    Time frame: Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks)

  5. Results on body temperature

    Descriptive statistics will be presented for the results of body temperature by time point.

    Time frame: Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks)

  6. Results on pulse

    Descriptive statistics will be presented for the results of pulse by time point.

    Time frame: Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks)

  7. Results on blood pressure

    Descriptive statistics will be presented for the results of blood pressure by time point.

    Time frame: Baseline, Each cycle(FOLFOX: each cycle is 14 days, XELOX or Capacitabine: each cycle is 21 days), Month 3 (13 weeks ± 2 weeks), Month 6 (26 weeks ± 2 weeks), Month 12 (52 weeks ± 4 weeks), Month 24 (104 weeks ± 8 weeks), Month 36 (156 weeks ± 8 weeks)

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Feb 2027, 83 months after the start.

Of 225 observational studies under Colonic Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 116. This study's planned 83 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2020
First posted
Jun 4, 2020
StartActual
Mar 25, 2020
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04416490
Responsible party
Sponsor
First posted
Jun 4, 2020
Start date
Mar 25, 2020
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 12, 2025

Study contacts

Myung Sook Hong
study director · Boryung Pharmaceutical Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion